Advanced search
Publication Cover
Future Virology Volume 2, 2007 - Issue 1
Submit an article Journal homepage
105
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacokinetics of Experimental Antiretroviral Agents

Tristan J BarberImperial College,Division of Medicine,London,UK Tel.: +44 207 886 6738; Fax.: +44 207 886 6123; [email protected]
&
Alan WinstonCorrespondence[email protected]
Pages 39-48 | Published online: 20 Dec 2006

Bibliography

  • Gazzard B : British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.HIV Med.6(Suppl. 2), 1–61 (2005).
  • Cahn P , ReussF, RolonMet al.: A Phase I study to explore the safety, tolerability, and pharmacokinetics of fosalvudine tidoxil in patients infected with HIV-1. Presented at: XVI International AIDS Conference.Toronto, Canada, 13–18August (2006).
  • Colucci P , PottageJ, RobinsonHet al.: Efficacy and novel pharmacology of elvucitabine in a 7 day placebo controlled monotherapy study. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy.San Fransisco, CA, 27–30September (2006).
  • Andries K , AzijnH, ThielemansTet al.: TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.Antimicrob. Agents Chemother.48(12), 4680–4686 (2004).
  • Gruzdev B , RakhmanovaA, DoubovskayaEet al.: A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.AIDS17(17), 2487–2494 (2003).
  • Gazzard BG , PozniakAL, RosenbaumWet al.: An open-label assessment of TMC125 – a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.AIDS17(18), F49–F54 (2003).
  • Piscitelli S , BaedeP, DedierG, van‘tKlooster N, GrahamN: Pharmacokinetics of TMC125 in HIV Infected Patients and Healthy Volunteers. Presented at: 3rd International Workshop on Clinical Pharmacology of HIV Therapy.Washington DC, USA, 13April (2002).
  • Baede P , PiscitelliS, GrahamN, van‘tKlooster GA: Drug interactions with TMC125, a potent next generation non-nucleoside reverse transcriptase inhibitor. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.San Diego, CA, USA, 27–30September (2002).
  • Piscitelli S , BaedeP, van‘tKlooster GA, GrahamN: TMC125, a potent next generation NNRTI, does not alter lopinavir/ritoavir pharmacokinetics in healthy volunteers. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.San Diego, CA, USA, 27–30September (2002).
  • Scholler M , HoetelmansR, BollenSet al.: No significant interaction between TMC125 and didanosine (DDI) in healthy volunteers. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy.Quebec, Canada, 28–30April (2005).
  • Schöller M , HoetelmansR, BollenSet al.: No significant interaction between TMC125 and didanosine (ddI) in healthy volunteers. Presented at: 3rd International AIDS Society Meeting.Rio de Janerio, Brazil, 8August (2006).
  • Scholler M , HoetelmansR, BeetsGet al.: Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy.Quebec, Canada, 28–30April (2005).
  • Scholler-Gyure M , LeemansR, BeetsGet al.: Effect of food on the oral bioavailability of the Phase III formulation of RMC125. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Schöller M , KraftM, HoetelmansRet al.: Significant decrease in TMC125 exposures when coadministered with tipranavir boosted with ritonavir in healthy subjects. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.Denver, CO, USA, 5–8February (2006).
  • Schöller-Gyüre M , WoodfallB, VanakenHet al.: Lack of interaction between TMC125 and methadone. Presented at: 16th World AIDS Conference.Toronto, Canada, 13–18August (2006).
  • Scholler-Gyure M , DebroyeC, VynckeVet al.: Effect of TMC125 of Sildenafil pharmacokinetics. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Goebel F , YakovlevA, PozniakAet al.: TMC278: Potent anti-HIV activity in antiretroviral therapy-naive patients. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA, 22–25February (2005).
  • Hoetelmans R , KestensD, MarienKet al.: Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy.Quebec, Canada, 28–30April (2005).
  • Hoetelmans R , KestensD, StevensMet al.: Pharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhbitior (NNRTI) TMC278 and tenofovir disoproxil fumarate (tdf) in healthy volunteers. Presented at: 6th Inernational Workshop on Clinical Pharmacology of HIV Therapy.Queveb, Canada, 28–30April (2005).
  • Hoetelmans R , Van HeeswijkR, KestensDet al.: Pharmacokinetic interaction between TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) and lopinavir/ritonavir (LPV/r) in healthy volunteers. Presented at: 10th European AIDS Conference.Dublin, Ireland, 17–20November (2005).
  • van Heeswijk R , HoetelmansR, KestensDet al.: The effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • van Heeswijk R , HoetelmansR, KestensDet al.: The pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy HIV-negative subjects. Presented at: XVI International AIDS Conference.Toronto, Canada, 11–16August (2006).
  • Huaug F , koenen-BergmannM, MacGregorTet al.: Pharmacokinetics of BILR355 after single ascending doses alone and in combination with 100 mg ritonavir (RTV) in healthy volunteers. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Huaug F , DrdaK, SchererJet al.: Phamraockinetics of BILR355 after multiple ascending doses co-administered with ritonavir in healthy volunteers. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • de Meyer S , AzijnH, SurlerauxDet al.: TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.Antimicrob. Agents Chemother.49(6), 2314–2321 (2005).
  • Hoetelmans R , vander Sandt I, dePauw Met al.: TMC114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers. Presented at: 10th Conference on Retroviruses and Opportunistic Infections.Boston, NE, USA, 10–14 February (2003).
  • Kwan WS , ChandlerB, HolmesRet al.: Influence of drug efflux transporters on cellular accumulation of darunavir (TMC114).7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Sekar V , KestensD, Spinosa-GuzmanSet al.: The effects of different meal types on the pharmacokinetics of TMC114 tablet formulation dosed with ritonavir in healthy volunteers. Presented at: 10th European AIDS Conference.Dublin, Ireland, 17–20November (2005).
  • Schon A , delmar Ingaramo M, FreireE: The binding of HIV-1 protease inhibitors to human serum proteins.Biophys. Chem.105(2–3), 221–230 (2003).
  • Sekar V , GuzmanS, StevensTet al.: Absolute bioavailability of TMC114, administered in the absence and presence of low-dose ritonavir. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Winston A , BoffitoM: The management of HIV-1 protease inhibitor pharmacokinetic interactions.J. Antimicrob. Chemother.56(1), 1–5 (2005).
  • Sekar V , HoetelmansR, deMarez Tet al.: Pharmacokinetics of TMC114: effect of omeprazole and ranitidine. Presented at: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment.Rio de Janeiro, Brazil, 24–27 July (2005).
  • Hoetelmans R , MarienK, dePauw Met al.: Pharmacokinetic interaction between TMC114/ritonavir (RTV) and tenofovir in healthy volunteers. Presented at: XVth World AIDS Conference.Bangkok, Thailand, 11July (2004).
  • Sekar V , de MarezT, GuzmanSet al.: Pharmacokinetic interaction between TMC114/ritonavir and atazanavir in healthy volunteers. Presented at: 10th European AIDS Conference.Dublin, Ireland, 17–20 November (2005).
  • Sekar V , DepaepeE, VangeneugdenTet al.: Absence of an interaction between the potent HIV protease inhibitor TMC114 and the fusion inhibitor enfuvirtide in the POWER 3 analysis. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Sekar V , DepauwM, MarienKet al.: No clinically significant pharmacokinetic drug–drug interaction is observed between the HIV protease inhibitor TMC114 and the non-nucleoside reverse transcriptase inhbitor efavirenz. Presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Hoetelmans R , LasureA, KoesterAet al.: The effect of TMC114, a potent next-generation hiv protease inhibitor, with low-dose ritonavir on atorvastatin pharmacokinetics. Presented at: 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.Washington DC, 30October–2 November October (2004).
  • Boffito M , WinstonA, FletcherCet al.: Pharmacokinetic and ART response to TMC114/r and TMC125 in combination in Patients with high level resistance. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.Denver, CO, 5–8February (2006).
  • Hazen R , St ClairM, HanlonMet al.: GW0385, a broadspectrum, ultrapotent inhibitor of wild-type and protease-inhibitor-resistant HIV-1. Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment.Paris, France, 13–16 July (2003).
  • Reddy S , FordSL, SteinDSet al.: Single-dose safety and pharmacokinetics (PK) of GW640385X (385): an HIV-1 protease inhibitor (PI). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy.Chicago, USA, 14–17September (2003).
  • Ford SL , SheltonMJ, MurraySCet al.: A Study to Investigate the Interaction between 640385/ritonavir (640385/r) and tenofovir (TDF) in Healthy Subjects. Presented at: 45th International Conference on Antimicrobial Agents and Chemotherapy.Washington DC, USA, 16–19December (2005).
  • Ford SL , MurrayS, AndersonMet al.: Brecanavir/ritonavir and atazanavir/ritonavir increased following repeat co-administration. Presented at: 7th Inernational Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Shelton MJ , FordS, AndersonMT, MurrayS, Ng-CashinJ: Overview of drug interactions between brecanavir (BCV) and other HIV protease inhibitors (PIs). Presented at: XVI International AIDS Conference.Toronto, Canada, 11–16August (2006).
  • Moyle G , LalezariJ: Aplaviroc clinical development suspended and vicriviroc naive study stopped by DSMB.J. Viral Entry1(2), 47 (2005).
  • Winston A , MallonPW, BoffitoM: The clinical pharmacology of antiretrovirals in development.Expert Opin. Drug Metab. Toxicol.2(3), 447–458 (2006).
  • Abel S , vander Ryst E, MuirheadGJet al.: Pharmacokinetics of single and multiple oral doses of UK-427,857 – a novel CCR5 antagonist in healthy volunteers. Presented at: 10th Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA10–14February (2003).
  • Sparks S , AdkisonK, Shachoy-ClarkA, PiscitelliS, DemarestJ: Prolonged duration of CCR5 occupancy by 873140 in HIV-negative and HIV-positive subjects. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.Boston, MA, USA22–25February (2005).
  • Demarest J , AdkisonK, SparksSet al.: Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 receptor antagonist, in healthy subjects. Presented at: 11th Conference on Retroviruses and Opportunistic Infections.San Fransisco, CA, USA, 8–11February (2004).
  • Abel S , RussellD, RidgwayC, MuirheadG: Overview of the drug–drug interaction data for maraviroc (UK-427,857). Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy.Quebec City, Canada, 28–30April (2005).
  • Nair V : Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agents.Curr. Pharm. Des.9(31), 2553–2565 (2003).
  • Gratton S , CheynierR, DumaurierMJ, OksenhendlerE, Wain-HobsonS: Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers.Proc. Natl Acad. Sci. USA97(26), 14566–14571 (2000).
  • Morales-Ramirez JO , TepplerH, KovacsCet al.: Antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in ART-naive HIV infected patients. Presented at: 10th European AIDS Conference.Dublin, Ireland, 17–20November (2005).
  • Miller M , WitmerM, StillmockKet al.: Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor. Presented at: XVI World AIDS Conference.Toronto, Canada, 12–17August (2006).
  • Grinsztejn B , NguyenB, KatlamaCet al.: Potent efficacy of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus: 24-week data.46th Interscience Conference on Antimicrobial Agents and Chemotherapy.San Fransisco, CA, USA (September2006).
  • Dupuis ML , CianfrigliaM, CostiRet al.: HIV-1 integrase inhibitors are potent substrates for the MDR1 multidrug transporter. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.Denver, CO, USA, 5–9February (2006).
  • Kawaguchi I , IshikawaT, IshibashiM, IrieS, KakeeA: Safety and pharmacokinetics of single oral dose of JTK-303/GS 9137, a novel HIV integrase inhibitor, in healthy volunteers. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.Denver, CO, USA, 5–9 February (2006).
  • Dejesus E , BergerD, MarkowitzMet al.: Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.J. Acquir. Immune Defic. Syndr.43(1), 1–5 (2006).
  • Kearney B , MathiasA, ZhongLet al.: Pharmacokinetic/pharmacodynamics of GS-9137 an HIV integrase inhibitor in treatment-naive and experienced patients. Presented at: 7th Inernational Workshop on Clinical Pharmacology of HIV Therapy.Lisbon, Portugal, 20–22April (2006).
  • Ramanathanm S , LaganK, PlummerAet al.: Lack of clinically relevant drug–drug interaction between the ritonavir-boosted HIV integrase inhibitor GS-9137/r and zidovudine (ZDV). Presented at: XVI International AIDS Conference.Toronto, Canada, 11–16August (2006).
  • Ramanathan S , SkillingtonJ, PlummerAet al.: Lack of clinically relevant drug–drug interaction between ritonavir-boosted GS-9137 (GS-9137/r) and emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF). Presented at: XVI International AIDS Conference.Toronto, Canada, 11–16August (2006).
  • Kaplan AH , ZackJA, KniggeMet al.: Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.J. Virol.67(7), 4050–4055 (1993).
  • Li F , Goila-GaurR, SalzwedelKet al.: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.Proc. Natl Acad. Sci. USA100(23), 13555–13560 (2003).
  • Martin DE , SmithP, Goila-GaurRet al.: Determinants of activity, in vitro metabolism and in vivo disposition of the novel maturation inhibitor PA-457. Presented at: 11th Conference on Retroviruses and Opportunistic Infections.San Fransisco, CA, USA, 8–11February (2004).
  • Martin DE , BallowCH, BlumRet al.: The safety, tolerability and pharmacokinetics of PA-457, a first-in-class, HIV maturation inhibitor, in healthy volunteers. Presented at: 7th International Congress on Drug Therapy for HIV Infection.Glasgow, UK, 14–18November (2004).
  • Smith P , ForrestA, BeattyGet al.: Pharmacokinetics/pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.Denver, CO, USA, 5–9 February (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.